Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

84.01 0.26

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

83.7

Massimo

84.06

Metriche Chiave

By Trading Economics

Entrata

7M

-121M

Vendite

14M

25M

EPS

-1.14

Margine di Profitto

-481.149

Dipendenti

594

EBITDA

-5.8M

-132M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+2.03% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4.5B

8.9B

Apertura precedente

83.75

Chiusura precedente

84.01

Notizie sul Sentiment di mercato

By Acuity

65%

35%

298 / 340 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 ago 2026, 23:56 UTC

News

CACI International reported Q2 sales of $2.71 billion, exceeding expectations. Shares advanced in after-market trading following strong earnings and optimistic full-year guidance.

5 ago 2026, 23:56 UTC

Correlated Moves
News
Social Media

Magnolia Oil & Gas reported net income of $181.8 million and adjusted EPS of $0.99, exceeding estimates, contributing to after-market gains.

5 ago 2026, 23:56 UTC

Correlated Moves
News

Entergy Corp shares rose in after-market trading, supported by a $35 million contract awarded to ICF for energy efficiency programs.

5 ago 2026, 23:56 UTC

Correlated Moves
News

Uranium Energy Corp gains in after-market trading, influenced by Cameco's rise amid cautious market sentiment following a weak ADP employment report.

5 ago 2026, 23:51 UTC

News

Global Net Lease raised its 2026 FFO guidance to $0.82-$0.85, aligning with estimates, contributing to after-market gains following its earnings report.

5 ago 2026, 23:51 UTC

Social Media
News

UWM Holdings Corp shares are lower after announcing a $400 million rights offering and suspending its common dividend to focus on debt reduction.

5 ago 2026, 23:51 UTC

News

Forward Air Corp reported record Q2 revenue of $673 million. Analysts reacted positively, contributing to a sharp rise in shares during after-market trading.

5 ago 2026, 23:51 UTC

News
Social Media

American Superconductor Corp shares fell in after-market hours following first-quarter earnings that missed expectations and disappointing second-quarter guidance.

5 ago 2026, 23:51 UTC

News

Akebia Therapeutics shares fell in after-market trading following a second-quarter net loss of $8.9 million and declining revenue amid increased competition.

5 ago 2026, 23:51 UTC

News

Cooper-Standard Holdings reported a net loss of $18.8 million and an adjusted EPS of -$0.13, contributing to a decline in after-market hours.

5 ago 2026, 23:51 UTC

News

Goodyear Tire & Rubber Co. shares are trading higher in after-market hours following a second-quarter adjusted EPS loss of $0.61, better than expected.

5 ago 2026, 23:51 UTC

News
Social Media

Axon Enterprise reported Q2 revenue of $904 million but saw net income drop to $29 million. Shares fell significantly in after-hours trading.

5 ago 2026, 23:51 UTC

News

IDEXX Laboratories shares rise in after-hours trading as UBS raises price target to $670 while maintaining a Neutral rating.

5 ago 2026, 23:51 UTC

Social Media
News

eBay Inc reported second-quarter adjusted EPS of $1.60, surpassing estimates. Shares rose in after-market hours as revenue also exceeded expectations.

5 ago 2026, 23:51 UTC

News
Social Media

HubSpot shares are lower in after-hours trading despite Q2 revenue of $911.7 million and adjusted EPS of $3.26, amid a cautious Q3 outlook.

5 ago 2026, 23:51 UTC

Social Media
News

Expedia Group reported strong second-quarter results, with adjusted EPS of $5.76 and revenues of $4.32 billion. Shares are trading lower in after-market hours.

5 ago 2026, 23:51 UTC

News

Coeur Mining shares fell in after-market trading following second-quarter earnings of $0.12 per share, missing the consensus estimate of $0.32.

5 ago 2026, 23:46 UTC

Correlated Moves
News
Social Media

Matador Resources reported Q2 sales of $1.19 billion and a non-GAAP profit of $2.61 per share. Shares rose in after-market trading following the results.

5 ago 2026, 23:46 UTC

News

Rivian Automotive has secured a $1.25 billion partnership with Uber. Shares are lower in after-market trading amid cautious sentiment from weak U.S. employment data.

5 ago 2026, 23:46 UTC

News

Ohio directs AEP to protect customers from data center impacts.

5 ago 2026, 23:46 UTC

News

Western Union launches Stablecard, a digital wallet utilizing USDPT. Shares are lower in after-market trading, continuing a narrow performance range since Wednesday's close.

5 ago 2026, 23:46 UTC

Social Media
News

NVIDIA Corp shares advanced in after-market hours following a $3.4 billion cloud services agreement with Iren and renewed analyst confidence in the stock.

5 ago 2026, 23:42 UTC

News

Eli Lilly reported second-quarter revenue of $23 billion, raising its full-year guidance to $85 billion to $87 billion. Shares are higher in after-market trading.

5 ago 2026, 23:41 UTC

News

Victory Capital Holdings reported strong Q2 results, with adjusted EPS of $2.21 and sales of $435.4 million, driving shares higher in after-market hours.

5 ago 2026, 23:41 UTC

News

Qualys Inc reported second-quarter revenue of nearly $182.2 million, surpassing expectations, and shares are higher in after-market trading.

5 ago 2026, 23:41 UTC

News

Toast Inc shares are lower in after-market hours following a downgrade to neutral, reflecting concerns over valuation amid macroeconomic challenges and competition.

5 ago 2026, 23:41 UTC

News

Lumen Technologies shares are higher in after-market hours following a partnership with Amdocs to enhance enterprise service orchestration using AI-driven capabilities.

5 ago 2026, 23:41 UTC

News
Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

5 ago 2026, 23:41 UTC

News
Social Media

NN Inc reported strong Q2 results, raising full-year sales guidance to $460 million to $470 million. Shares are trading sharply higher in after-market hours.

5 ago 2026, 23:41 UTC

Social Media
News

Dutch Bros Inc. shares declined after strong Q2 results and guidance, amid investor concerns over the planned acquisition of Salad and Go locations.

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

2.03% in crescita

Previsioni per 12 mesi

Media 85.56 USD  2.03%

Alto 95 USD

Basso 80 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

2

Acquista

12

Mantieni

0

Vendi

Sentiment

By Acuity

298 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat